Tags

Type your tag names separated by a space and hit enter

Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.
Clin Endocrinol (Oxf). 1996 Jan; 44(1):121-4.CE

Abstract

The syndrome of pituitary apoplexy has been reported to occur after the administration of several different medications. We report a case in which pituitary apoplexy developed shortly after the administration of leuprolide in a patient with prostate cancer. Leuprolide is a potent gonadotrophin releasing hormone (GnRH) analogue used to suppress leuteotrophic hormone (LH) and testosterone levels in patients with metastatic prostate cancer. LH and testosterone levels actually rise in the first week after its administration before becoming suppressed. We suspect that this acute stimulating effect of leuprolide is linked to the acute onset of pituitary apoplexy in a patient with a possible gonadotrophoma.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Morsi A
Sunnybrook Health Science Centre, University of Toronto, Canada.
Jamal S
No affiliation info available
Silverberg JD
No affiliation info available

MeSH

Acute DiseaseAgedAntineoplastic Agents, HormonalGonadotropin-Releasing HormoneHumansLeuprolideMagnetic Resonance ImagingMalePituitary ApoplexyPituitary GlandProstatic NeoplasmsTomography, X-Ray Computed

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

8706284

Citation

Morsi, A, et al. "Pituitary Apoplexy After Leuprolide Administration for Carcinoma of the Prostate." Clinical Endocrinology, vol. 44, no. 1, 1996, pp. 121-4.
Morsi A, Jamal S, Silverberg JD. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. Clin Endocrinol (Oxf). 1996;44(1):121-4.
Morsi, A., Jamal, S., & Silverberg, J. D. (1996). Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. Clinical Endocrinology, 44(1), 121-4.
Morsi A, Jamal S, Silverberg JD. Pituitary Apoplexy After Leuprolide Administration for Carcinoma of the Prostate. Clin Endocrinol (Oxf). 1996;44(1):121-4. PubMed PMID: 8706284.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. AU - Morsi,A, AU - Jamal,S, AU - Silverberg,J D, PY - 1996/1/1/pubmed PY - 1996/1/1/medline PY - 1996/1/1/entrez SP - 121 EP - 4 JF - Clinical endocrinology JO - Clin Endocrinol (Oxf) VL - 44 IS - 1 N2 - The syndrome of pituitary apoplexy has been reported to occur after the administration of several different medications. We report a case in which pituitary apoplexy developed shortly after the administration of leuprolide in a patient with prostate cancer. Leuprolide is a potent gonadotrophin releasing hormone (GnRH) analogue used to suppress leuteotrophic hormone (LH) and testosterone levels in patients with metastatic prostate cancer. LH and testosterone levels actually rise in the first week after its administration before becoming suppressed. We suspect that this acute stimulating effect of leuprolide is linked to the acute onset of pituitary apoplexy in a patient with a possible gonadotrophoma. SN - 0300-0664 UR - https://www.unboundmedicine.com/medline/citation/8706284/Pituitary_apoplexy_after_leuprolide_administration_for_carcinoma_of_the_prostate_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0300-0664&date=1996&volume=44&issue=1&spage=121 DB - PRIME DP - Unbound Medicine ER -